insightSLICE

Pharmaceutical Manufacturing Market

Pharmaceutical Manufacturing Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
Frequently asked questions about this report

Pharmaceutical manufacturing market is anticipated to expand at a CAGR of 11.5% from 2023 to 2032.

Pharmaceutical manufacturing market size was estimated to be US$ 526 Billion in 2022.

The pharmaceutical manufacturing market is driven by several factors, including the increasing demand for medicines, advancements in technology, government support, and rising healthcare expenditure.

Conventional drugs segment accounted for the highest revenue share in the global pharmaceutical manufacturing market because of the fact that they have been in the market for a longer period of time and have a proven track record of safety and efficacy.

The pharmaceutical manufacturing market is dominated by the other disease segment.

The pharmaceutical manufacturing market is dominated by the North America, due to the presence of a large number of pharmaceutical companies and advanced healthcare infrastructure in the region.

AbbVie Inc., AstraZeneca, Bristol Myers Squibb Company, Cipla Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Novo Nordisk A/S, Pfizer, Inc.; Merck & Co., Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceuticals Inc, among others are the major players in pharmaceutical manufacturing market.

Key pharmaceutical manufacturing market players are AbbVie, Inc., AstraZeneca, Bristol Myers Squibb Company, Cipla Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Novo Nordisk A/S, Pfizer, Inc.; Merck & Co., Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceuticals, Inc., and many more.